Results 71 to 80 of about 32,363 (292)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm [PDF]

, 2016
Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of ...
Abozguia, AIRE Study Group, Alexander, Alexander, Alexander, Alexander, Ashrafian, Bailey, Bailey, Basu, Beadle, Braunwald, Brown, Burgoyne, Chaitman, Chatterjee, Chung, CIBIS-II Study Group, Cleland, Clerc, Cohn, Cohn, Cohn, CONSENSUS Trial Study Group, Conway, Cook, Dai, Digitalis Investigation Group, Doenst, Dzau, Dzau, Faris, Flather, Follath, Foster, Fox, Fox, Fragasso, Furberg, Gheorghiade, Gladwin, Goffart, Granger, Greenberg, Guazzi, Guazzi, Heymans, Hobbs, Holubarsch, Horowitz, Horowitz, Kantor, Kapil, Kato, Kennedy, Kennedy, Kostis, Larsen, Lee, Lopaschuk, Luiken, Lundberg, Maher, Maier, Mancini, Mann, Mann, Massie, Mccormack, Mcdowell, Mcmurray, Mcmurray, Merit-Hf Study Group, Munzel, Munzel, Neglia, Neubauer, Ormerod, Packer, Packer, Paul, Pawson, Pfeffer, Pfeffer, Pitt, Pitt, Rathore, Rauchhaus, Redfield, Rona, Sack, Sarraf, Schmidt-Schweda, Schrauwen, Schwarz, Shah, Shah, Siddiqi, Singh, SOLVD Investigators, Stanley, Swedberg, Szwed, Taylor, Teerlink, Tilemann, Torre-Amione, Totzeck, Turcani, Unger, Van Der Vusse, Van Faassen, Vardeny, Webb, Yin, Yusuf, Zamani, Zannad, Zannad, Zhang   +119 more
core   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients

BMC Nephrology, 2020
Background Peritoneal ultrafiltration (pUF) in refractory heart failure (HF) reduces the incidence of decompensation episodes, which is of particular significance as each episode incrementally adds to mortality.
Leonie Grossekettler, Bastian Schmack, Carsten Brockmann, Reinhard Wanninger, Michael M. Kreusser, Lutz Frankenstein, Lars P. Kihm, Martin Zeier, Hugo A. Katus, Vedat Schwenger, Andrew Remppis   +10 more
doaj   +1 more source

Mechanisms of sacubitril–valsartan benefit in HFrEF [PDF]

Nature Reviews Cardiology, 2019
Two studies reveal new details of the mechanisms underlying the benefits of the angiotensin receptor–neprilysin inhibitor sacubitril–valsartan in patients with heart failure and reduced ejection fraction, suggesting that sacubitril–valsartan induces reverse cardiac remodelling but has no effect in reducing central aortic stiffness.
openaire   +2 more sources

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model

Clinical Epidemiology, 2020
Moa P Lee,1,2 Robert J Glynn,1 Sebastian Schneeweiss,1 Kueiyu Joshua Lin,1,3 Elisabetta Patorno,1 Julie Barberio,1 Raisa Levin,1 Thomas Evers,4 Shirley V Wang,1 Rishi J Desai1 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women ...
Lee MP, Glynn RJ, Schneeweiss S, Lin KJ, Patorno E, Barberio J, Levin R, Evers T, Wang SV, Desai RJ   +9 more
doaj  

542 USE OF ANGIOTENSIN RECEPTOR/NEPRYLISIN INHIBITORS (ARNI) IN WILD TYPE TTR CARDIAC AMYLOIDOSIS (WTATTR) AND HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) : IS IT WORTH A TRY? [PDF]

, 2022
Bianca Fowler, Antonella Vincenzi, Paolo Massa, Didi Massabo, Eleonora Lo Vullo, Maddalena Lettino   +5 more
openalex   +1 more source

Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure [PDF]

, 2018
This study aimed to compare the effect of β-blocker dose and heart rate (HR) on mortality in patients with heart failure with reduced ejection fraction (HFrEF).
Ajam, Samer, Ajam, Tarek, Devaraj, Srikant, Fudim, Marat, Kamalesh, Masoor   +4 more
core   +1 more source